Dr. Knox is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
875 Blake Wilbur Dr
Dept Radiation Oncology Cancer Center
Palo Alto, CA 94304Phone+1 650-723-6171Fax+1 650-725-8231
Education & Training
Stanford Health Care-Sponsored Stanford UniversityResidency, Radiation Oncology, 1986 - 1990
University of California Davis HealthInternship, Internal Medicine, 1985 - 1986
Stanford University School of MedicineClass of 1985
Certifications & Licensure
CA State Medical License 1986 - 2024
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- Phase 2 Study of Bexxar in Relapsed/Refractory DLCL Start of enrollment: 2004 Sep 01
- Study of Bexxar <Tositumomab> Combined With External Beam Radiation Therapy Start of enrollment: 2007 Jan 01
- Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy Start of enrollment: 2011 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- 120 citationsAssessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tos...John M. Bennett, Mark S. Kaminski, John P. Leonard, Julie M. Vose, Andrew D. Zelenetz
Blood. 2005-06-15 - 95 citationsEnhancement of murine intestinal stem cell survival after irradiation by keratinocyte growth factor.Waqqar Khan, Chaoxiang Shui, Shoucheng Ning, Susan J. Knox
Radiation Research. 1997-09-01 - 190 citationsA Systemic Complete Response of Metastatic Melanoma to Local Radiation and ImmunotherapySusan M. Hiniker, Daniel S. Chen, Sunil Reddy, Daniel T. Chang, Jennifer Jones
Translational Oncology. 2012-12-01
Press Mentions
Dose-Dependent Nuclear Delivery and Transcriptional Repression with a Cell-Penetrant MeCP2February 22nd, 2023
Stanford Medical Students Celebrate Match Day VirtuallyMarch 22nd, 2021
Eighty-Five Medical Students Meet Their MatchesMarch 15th, 2019
Grant Support
- Protocol Review And Monitoring System (PRMS)National Cancer Institute2007–2009
- Clinical Trial: Phase II Study Of Bexxar In Relapsed/Refractory DlclNational Center For Research Resources2008
- Clinical Trial: Bexxar Combined With External Beam Radiation Therapy For PatientNational Center For Research Resources2008
- Phase II Study Of Bexxar In Relapsed/Refractory DlclNational Center For Research Resources2006–2007
- Anti B1 Antibody For Nonhodgkins LymphomaNational Center For Research Resources2000–2001
- Phase II Multicenter Trial Of 90 Yttrium DOTA Biotin In Subjects W/ CancerNational Center For Research Resources1999–2000
- Iodine Anti B1 Murine Radioimmunotherapy For Chemotherapy LymphomaNational Center For Research Resources1999–2000
- Anti-B1 (MURINE) In Chemotherapy-Refractory Low Grade Nonhodgkin'S LymphomaNational Center For Research Resources1997–2000
- Study Of 90 Yttrium/Dota/Biotin Localization In Advanced CancerNational Center For Research Resources1996–2000
- Pivotal Phase II/III Of Murine Radioimmunotherapy For LymphomasNational Center For Research Resources1998–1999
- BCL-2, Na+/K+ Atpase And Radiation Induced ApoptosisNational Cancer Institute1996–1998
- Radiobiology Of Low Dose Rate RadioimmunotherapyNational Cancer Institute1994–1997
- Intravenously Administered 90y-Cyi-356 In Metastatic Prostate CancerNational Center For Research Resources1996
- B Cell Lymphoma With 90y-Labeled B1 (Anti-Cd20) Monoclonal AntibodyNational Center For Research Resources1996
- Radiobiology Of Low-Dose Rate RadioimmunotherapyNational Cancer Institute1993
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
